{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:13:10Z","timestamp":1788577990266,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930080"],"award-info":[{"award-number":["81930080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272811"],"award-info":[{"award-number":["82272811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2023654"],"award-info":[{"award-number":["BE2023654"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216777","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T21:24:07Z","timestamp":1709328247000},"page":"216777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity"],"prefix":"10.1016","volume":"588","author":[{"given":"Yue","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-7732","authenticated-orcid":false,"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216777_bib1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","article-title":"Malignant pleural effusion: presentation, diagnosis, and management","volume":"135","author":"Gayen","year":"2022","journal-title":"Am. J. Med."},{"key":"10.1016\/j.canlet.2024.216777_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel","year":"2015","journal-title":"Respirology"},{"key":"10.1016\/j.canlet.2024.216777_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106802","article-title":"Update on the diagnosis and management of malignant pleural effusions","volume":"196","author":"Bashour","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.canlet.2024.216777_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2024.216777_bib5","article-title":"Current status of and progress in the treatment of malignant pleural effusion of lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216777_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3892\/ijo.2021.5174","article-title":"Novel therapies for malignant pleural effusion: Anti-angiogenic therapy and immunotherapy (Review)","volume":"58","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2024.216777_bib7","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.7150\/thno.85084","article-title":"Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer","volume":"13","author":"Wu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.216777_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion: tumor-host interactions unleashed","volume":"186","author":"Stathopoulos","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2024.216777_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1072","article-title":"Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216777_bib10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1378\/chest.126.5.1529","article-title":"Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer","volume":"126","author":"Ren","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.canlet.2024.216777_bib11","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/j.jtcvs.2020.11.160","article-title":"Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease","volume":"163","author":"Ekeke","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.canlet.2024.216777_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12885-018-4581-5","article-title":"Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients","volume":"18","author":"Han","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112960","article-title":"Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma","volume":"14","author":"Chintala","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216777_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model","volume":"122","author":"Iankov","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2024.216777_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216777_bib16","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216777_bib17","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216777_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1157697","article-title":"A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells","volume":"14","author":"Donnenberg","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216777_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105358","article-title":"Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma","volume":"25","author":"Jeong","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2024.216777_bib20","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.216777_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216777_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00018-022-04227-z","article-title":"Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion","volume":"79","author":"Niu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2024.216777_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/eji.201847685","article-title":"IL-10 promotes malignant pleural effusion in mice by regulating TH 1- and TH 17-cell differentiation and migration","volume":"49","author":"Wu","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2024.216777_bib24","article-title":"Bacteria-based cancer immunotherapy","volume":"8","author":"Huang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.216777_bib25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/1097-0142(19880815)62:4<806::AID-CNCR2820620428>3.0.CO;2-4","article-title":"Treatment of malignant pleural effusions with intracavitary Corynebacterium parvum","volume":"62","author":"Casali","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s004300050026","article-title":"Effects on antitumor activity and cytokine production in the thoracic cavity by intrapleural administration of Lactobacillus casei in tumor-bearing mice","volume":"185","author":"Matsuzaki","year":"1996","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.canlet.2024.216777_bib27","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","article-title":"Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216777_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/IJN.S237536","article-title":"The safety and exploration of the pharmacokinetics of intrapleural liposomal curcumin","volume":"15","author":"Hocking","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2024.216777_bib29","first-page":"11","article-title":"A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer","author":"Nie","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061664","article-title":"Anatomical targeting of anticancer drugs to solid tumors using specific administration routes: review","volume":"15","author":"Saito","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2024.216777_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9789","article-title":"Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming","volume":"6","author":"Wan","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.216777_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-015-0662-2","article-title":"A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells","volume":"13","author":"Acencio","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216777_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1165\/rcmb.2005-0130OC","article-title":"Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion","volume":"34","author":"Stathopoulos","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.canlet.2024.216777_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/07853890.2022.2071977","article-title":"Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy","volume":"54","author":"Xiang","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.canlet.2024.216777_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1032","article-title":"Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors","volume":"8","author":"Nash","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.216777_bib36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","article-title":"Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy","volume":"16","author":"Wang","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.canlet.2024.216777_bib37","first-page":"181","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216777_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.canlet.2024.216777_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.lungcan.2018.06.002","article-title":"Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review","volume":"122","author":"Bibby","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib40","first-page":"3556","article-title":"Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial","volume":"15","author":"Cheng","year":"2023","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.canlet.2024.216777_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2016.12.015","article-title":"Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion","volume":"104","author":"Sakaguchi","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00280-011-1765-y","article-title":"Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis","volume":"69","author":"Lombardi","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216777_bib43","first-page":"11","article-title":"C1q+ tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004239","article-title":"Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients","volume":"10","author":"Bruschini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","article-title":"Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion","volume":"452","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216777_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canlet.2020.06.014","article-title":"Platelet factor 4 regulates T cell effector functions in malignant pleural effusions","volume":"491","author":"Mulet","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216777_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760683","article-title":"Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216777_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2160558","article-title":"Altered phenotypic and metabolic characteristics of FOXP3+CD3+CD56+ natural killer T (NKT)-like cells in human malignant pleural effusion","volume":"12","author":"Wang","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216777_bib49","series-title":"Immunotherapeutic Agents for Intratumoral Immunotherapy","first-page":"11","author":"Shyr","year":"2023"},{"key":"10.1016\/j.canlet.2024.216777_bib50","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/ijc.30289","article-title":"Impaired T cell function in malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages","volume":"139","author":"Li","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216777_bib51","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-l1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:39:53Z","timestamp":1760816393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S0304383524001708"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216777","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216777"}}